ANAkshata Nandanwar

Akshata Nandanwar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Akshata Nandanwar has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perspectives of in silico studies on Cow Urine Distillate as a Bioenhancer in Infectious and Non-infectious disease therapeutics: A Review

    by Prachi Dabhade, Akshata Nandanwar, Amit Nayak, Aliabbas Husain, Nandini Bhojraj, R. Govind Reddy, U.R. Sekhar Namboori, Rajpal Singh Kashyap

    The global rise in anti-microbial resistance with the limited bioavailability and suboptimal pharmacokinetic performance of conventional therapeutics, it has intensified the interest in natural bioenhancer capable of improving therapeutics, having intensified the interest in natural bioenhancer thus capable of improving therapeutic efficacy across infectious and non-infectious disease settings. Cow urine distillate (CUD), an Ayurvedic preparation, has showcased the immunomodulatory, anti-inflammatory, antimicrobial, and bioavailability-enhancing properties. The in-silico investigation explored CUD-derived bioactive constituents as a multi-target bioenhancer, having its key role on vivid and diverse molecular pathways that act in fungal, parasitic, bacterial, viral, inflammatory, and immune-mediated disorders. Computational studies have revealed the CUD phytochemicals and key pathogen targets, like penicillin-binding protein 2a (PBP2a), topoisomerase IV, viral proteases, β-tubulin, and glutathione S-transferase, RNA-dependent RNA polymerase, lanosterol 14-α-demethylase (CYP51), host-regulatory targets such as cyclooxygenase-2 (COX-2), nuclear factor-κB (NF-κB), and Toll-like receptors. Literature suggests that primary constituents, including cinnamic acid, ferulic acid, indole, and hexanoic acid, are evaluated by in silico tools like AutoDock Vina, MOE, and Schrödinger Glide, Molecular Dynamics (MD) simulations to assess binding stability and conformational behavior. Molecular Docking results are indicative of stable binding affinities and in silico ADMET analyses by using SwissADME and pkCSM, predicting favorable oral bioavailability and low toxicity profiles compatible with adjunctive use. Network pharmacology analyses support a polypharmacological mode of action targeting both pathogen survival pathways and host immune-inflammatory signaling. The available in silico evidence proves CUD as a promising multi-target bioenhancer; systematic in vitro and in vivo validation are essential to substantiate its translational potential.

  • Open Access

    Computational Insights on Cow urine distillate used as a Bioenhancer in Cancer Therapy

    by Prachi Dabhade, Akshata Nandanwar, Amit Nayak, Aliabbas Husain, Nandini Bhojraj, Govind Reddy, U.R. Sekhar Namboori, Rajpal Singh Kashyap

    Cancer poses a significant global health burden, aligning conventional therapies limited by poor drug bioavailability, systemic toxicity, and the development of chemoresistance. The aligning challenges have showcased the growing interest in natural bioenhancers, which are capable of improving therapeutic efficacy while mitigating adverse effects. Cow urine distillate (CUD), a traditional Ayurvedic preparation that is derived from Bos indicus, holds impressive research data in terms of immunomodulatory, antioxidant, and bioavailability-enhancing properties. CUD constitutes phytochemicals like ferulic acid, cinnamic acid, and phenylethanol, and cinnamic acid shows favorable binding affinities in docking studies performed with in silico tools like AutoDock Vina, Schrödinger Glide, and Molecular Operating Environment. As the research literature indicates, molecular dynamics simulations show a stable ligand receptor with reported minimal conformational fluctuation. The in silico investigations has revealed the potential of CUD derived phytochemicals as adjuvants in oncology with the primary cancer associated molecular targets including Cyclin dependent kinases, DNA topoisomerase II, epidermal growth factor receptor (EGFR), phosphoinositide 3-kinase (PI3K), vascular endothelial growth factor receptor (VEGFR), protein kinase B (Akt), Bcl-2, and matrix metalloproteinases are widely researched and explored using high-resolution structures from the Protein Data Bank. In silico ADMET profiling ensured by SwissADME and pkCSM gives good oral absorption, drug-likeness, and low predicted toxicity, supporting translational feasibility. Network pharmacology analyses have reported multi-target modulation of pathways controlling apoptosis, proliferation, angiogenesis, inflammation, immune response, and therapeutic resistance. Computational insights give the rationale for the mechanism for CUD as a multitarget natural bioenhancer. Showing the need for systematic in vitro, in vivo, and clinical studies to validate its bioenhancing and adjunctive potential in cancer therapeutics.